Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis, is a chronic, progressive inflammatory condition that primarily affects the spine and sacroiliac joints. It belongs to the family of spondyloarthropathies and can lead to severe back pain, morning stiffness lasting more than 30 minutes, reduced spinal mobility, and in advanced cases, fusion of the vertebrae (ankylosis), resulting in a “bamboo spine” appearance on X-rays.
AS often begins in early adulthood, typically between ages 20-30, and affects men more frequently than women, though women are increasingly recognized as having significant disease burden. Beyond the spine, it can involve peripheral joints, entheses (where tendons/ligaments attach to bone), eyes (uveitis), and the gut (inflammatory bowel disease). Fatigue, sleep disturbances, and reduced quality of life are common. While there is no cure, early diagnosis and appropriate medication can dramatically improve symptoms, function, and prevent irreversible damage.
Medications form the backbone of AS management. They work by reducing inflammation, alleviating pain and stiffness, and in many cases, slowing structural progression. Treatment is always personalized, considering disease severity, comorbidities (like heart disease, infections, or IBD), patient lifestyle, and preferences. A multidisciplinary approach—including physical therapy, exercise, smoking cessation, and regular monitoring—is essential alongside drugs.
Important Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Medications for AS can have serious side effects and require careful monitoring by a rheumatologist. Always consult your healthcare provider before starting, stopping, or changing any treatment. Information is current as of 2026 and reflects major guidelines like ASAS-EULAR 2022 and national updates.
Understanding the Goals of Medication Therapy
The primary goals are to achieve remission or low disease activity, measured by tools like the Ankylosing Spondylitis Disease Activity Score (ASDAS) or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Treatment follows a “treat-to-target” strategy: start with simpler options, escalate if targets aren’t met after adequate trials (typically 4-12 weeks), and regularly reassess.
Key principles from ASAS-EULAR recommendations include:
- NSAIDs as first-line pharmacological therapy.
- Biologics or targeted therapies for inadequate responders.
- Personalized choices based on extra-musculoskeletal manifestations (e.g., uveitis, psoriasis, IBD).
- Avoidance of long-term systemic steroids or conventional DMARDs for pure axial disease.
It is very important to openly talk to your doctor about your medicines so you can work together to find the most effective and safe treatment plan for your AS.
1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): The Foundation
NSAIDs remain the first-line treatment for active AS. They are recommended continuously or on-demand for symptom control and are effective in reducing pain and stiffness in up to 70-80% of patients.
Common Options:
- Non-selective: Ibuprofen, naproxen, diclofenac, indomethacin.
- COX-2 selective: Celecoxib (Celebrex), etoricoxib (in some regions).
Mechanism: They inhibit cyclooxygenase enzymes (COX-1/COX-2), reducing prostaglandin production that drives inflammation and pain.
Dosing and Use: Full anti-inflammatory doses for at least 2-4 weeks per drug. Guidelines suggest trying at least two different NSAIDs before advancing. Some patients experience dramatic relief within days.
Benefits: Readily available (many over-the-counter), fast onset, and may have mild disease-modifying effects in early disease.
Risks and Management:
- Gastrointestinal (GI): Ulcers, bleeding — mitigated by proton pump inhibitors (PPIs) like omeprazole.
- Cardiovascular: Increased risk of heart attack/stroke, especially with long-term use.
- Kidney: Potential impairment, requiring blood pressure and renal function monitoring.
- Other: Liver effects, allergic reactions.
Patients with high CV risk may prefer COX-2 selectives, though all carry warnings. Regular check-ups (every 3-6 months) are crucial for long-term users.
2. Corticosteroids: For Flares and Targeted Relief
Oral steroids like prednisone are not recommended for routine long-term use in axial AS due to limited spinal efficacy and high side-effect burden. They are reserved for acute flares or bridging while starting other therapies.
Preferred Approaches:
- Local injections: Into sacroiliac joints, peripheral joints, or entheses under imaging guidance.
- Short courses (e.g., 1-2 weeks tapering) for severe systemic flares.
Side Effects: Osteoporosis (bone loss — counter with calcium/vitamin D/bisphosphonates), weight gain, hypertension, diabetes, cataracts, mood changes, and infection risk. Bone density scans (DEXA) are advised for prolonged exposure.
3. Conventional Synthetic DMARDs (csDMARDs): Limited Role in Axial Disease
These older drugs (sulfasalazine, methotrexate, leflunomide) have modest benefits mainly for peripheral arthritis or co-existing conditions like IBD, but poor efficacy for spinal inflammation.
- Sulfasalazine: 2-3g daily; useful for peripheral joints or gut involvement.
- Methotrexate: More effective in psoriatic arthritis; limited axial benefit.
They are generally not recommended as primary therapy for pure axial AS per major guidelines.
4. Biologic DMARDs (bDMARDs): Game-Changers for Moderate-to-Severe AS
Biologics are injected or infused proteins that target specific immune pathways. They are indicated after NSAID failure in patients with active disease (high ASDAS, elevated CRP, or imaging inflammation).
TNF Inhibitors (TNFi) — The Longest-Standing Class
These block tumor necrosis factor-alpha, a central cytokine in AS inflammation. Five main options (plus biosimilars):
- Adalimumab (Humira) and biosimilars: Subcutaneous injection every 1-2 weeks.
- Etanercept (Enbrel): Weekly injection (fusion protein, not monoclonal antibody).
- Infliximab (Remicade) and biosimilars: IV infusion every 6-8 weeks.
- Golimumab (Simponi): Monthly injection.
- Certolizumab pegol (Cimzia): Every 2-4 weeks.
Efficacy: 50-70% achieve significant improvement (ASAS40 response). They reduce symptoms, improve function, and may slow radiographic progression. Monoclonal antibodies (adalimumab, infliximab, etc.) are preferred over etanercept for patients with recurrent uveitis or IBD.
Safety: Increased infection risk (TB screening mandatory before starting), injection reactions, possible heart failure worsening, or demyelinating disease. Long-term data (20+ years) show good tolerability in most.
IL-17 Inhibitors: Targeting Another Key Pathway
These block interleukin-17, important in enthesitis and new bone formation.
Approved Options:
- Secukinumab (Cosentyx): Monthly after loading.
- Ixekizumab (Taltz): Every 4 weeks.
- Bimekizumab (Bimzelx): Approved 2024 for AS; dual IL-17A/F inhibitor.
When Preferred: Excellent for patients with prominent psoriasis. Comparable efficacy to TNFi in many studies. Not ideal as first-choice for active IBD (may worsen it).
Side Effects: Candida (yeast) infections, upper respiratory infections, inflammatory bowel disease exacerbation (rare).
5. Janus Kinase (JAK) Inhibitors: Oral Targeted Therapies
These small-molecule drugs block intracellular signaling for multiple cytokines.
Approved for AS:
- Upadacitinib (Rinvoq): Once-daily oral.
- Tofacitinib (Xeljanz): Twice-daily.
Advantages: Convenient pills; rapid onset; effective after TNFi failure.
Concerns: Black-box warnings for serious infections, blood clots (VTE), major cardiovascular events, cancer, and mortality (especially in older patients or those with risk factors). Screening and monitoring (lipids, blood counts) are intensive. Often used after biologics in many protocols.
Treatment Algorithm and Sequencing
- NSAIDs + Non-Drug Measures (exercise, PT, posture training).
- Biologic (TNFi or IL-17i) if inadequate response.
- Switch to another bDMARD (different mechanism) or JAKi.
- Re-evaluate diagnosis and comorbidities if multiple failures.
Biosimilars have improved access and reduced costs significantly.
Managing Side Effects and Monitoring
All advanced therapies suppress immunity — stay up-to-date on vaccinations (avoid live vaccines during treatment). Regular labs (CBC, liver/kidney function, lipids), TB screening, and clinical assessments every 3-6 months. Report fevers, coughs, or skin changes promptly.
Emerging Therapies and Future Directions
Research focuses on:
- New IL-17/23 inhibitors.
- Bispecific antibodies.
- Gut microbiome modulation.
- Personalized medicine based on genetics/imaging.
Biosimilars and oral options continue expanding.
Holistic Management and Lifestyle Integration
Medications work best with:
- Daily exercise (swimming, yoga, stretching).
- Anti-inflammatory diet (Mediterranean-style).
- Good sleep hygiene.
- Mental health support (chronic pain can lead to anxiety/depression).
- Smoking cessation (worsens progression dramatically).
Many patients achieve excellent control and maintain active lives.
Frequently Asked Questions (FAQs)
How long do I need to take these medications?
Often long-term, but tapering may be attempted in sustained remission.
Are biologics safe during pregnancy?
Many require planning; some TNFi are safer. Discuss with specialists.
What if cost is an issue?
Patient assistance programs, biosimilars, and insurance appeals help.
Can I stop if I feel better? Relapse is common; follow medical guidance.
Conclusion: Hope and Proactive Management
Ankylosing Spondylitis is manageable with today’s medications. From NSAIDs to advanced biologics and JAK inhibitors, options have transformed outcomes. Early intervention is key — don’t delay seeing a rheumatologist if you suspect AS.
Work closely with your care team, track symptoms (apps or journals help), and advocate for yourself. Many live full, productive lives with proper treatment. Stay informed as research advances rapidly.